PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629186
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629186
Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market End User was valued at USD 5,620.32 Million in 2023, expanding at a CAGR of 8.30% from 2024 to 2032.
The Diphtheria, Pertussis, and Tetanus (DPT) vaccine is a combination vaccine that provides protection against serious bacterial infections. These vaccines reduce the risk of infection and serious complications, especially in young children.
Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market- Market Dynamics
Increasing prevalence of DPT-related diseases among infant & children and rising awareness spread by government programs is expected to propel market demand
Increased efforts by governments and organizations to educate populations about the importance of vaccination is promoting market growth. Programs like WHO's Expanded Program on Immunization (EPI) and GAVI, the Vaccine Alliance, emphasize the need for widespread immunization against DPT-related diseases. Improved understanding of the risks of diphtheria, pertussis, and tetanus, particularly in children, drives demand. Also, the inclusion of the DPT vaccine in national immunization schedules boosts market demand. Many governments provide vaccines at little or no cost, making them accessible to underserved populations.
Infants and young children are particularly susceptible to DPT-related diseases. In the countries or regions with high birth rates, such as Africa and parts of Asia, the growing number of children under five drives the need for DPT vaccines. DPT is often combined with other vaccines like hepatitis B, polio for ease of administration, improving market penetration. Additionally, advancements in vaccine storage and distribution enhance accessibility in remote areas. Periodic pertussis outbreaks due to waning immunity have underscored the need for booster doses and high vaccination rates. Eradication and control efforts for diseases like diphtheria and pertussis prioritize DPT vaccines. Initiatives like maternal and neonatal tetanus (MNT) elimination programs support consistent vaccine uptake.
Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.30% over the forecast period (2024-2032)
Based on Type segmentation, the DTaP vaccines segment was predicted to show maximum market share in the year 2023, mainly owing to WHO's recommendation.
Based on Age Group segmentation, the pediatrics segment was the leading Age Group segment in 2023, due to mandatory DTP vaccines made by WHO norms.
Based on End User segmentation, the hospitals segment was the leading End User segment in 2023, mainly due to rising awareness among people about vaccination & programs by hospitals.
On the basis of region, Asia Pacific was the leading revenue generator in 2023, due to the rise in the population across Asian countries.
Global Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market is segmented on the basis of Type, Age Group, End User, and Region.
The market is divided into three categories based on the Type: DTaP vaccines, TD vaccines, and TDaP vaccines. The DTaP vaccines segment dominates the market. The growing need to prevent infectious disease prevalence is boosting segment growth.
The market is divided into two categories based on Age Group: adults and pediatrics. The pediatrics segment dominates the market. The increasing awareness among pediatrics groups about pre-vaccination programs is primarily supplementing segment growth.
The market is divided into three categories based on End User: hospitals, clinics, and others. The hospital segment is anticipated to grow at the fastest rate over the forecast period. The growing number of vaccination programs with WHO & UNICEF goals with maternal tetanus elimination, polios are expected to foster market demand.
Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. In North America, there is high vaccination coverage due to stringent public health mandates. Established healthcare infrastructure ensures widespread vaccine access. In Asia Pacific, rapidly growing due to high birth rates and large infant populations in countries like India, China, and Southeast Asia. Support from global organizations such as GAVI, WHO for immunization programs in low-income areas. India and China are major markets, both as vaccine consumers and producers.
The Diphtheria, Pertussis, and Tetanus (DPT) vaccine market is characterized by intense competition among major pharmaceutical companies, continuous innovations, and strategic partnerships. The market is moving towards advanced combination vaccines like pentavalent and hexavalent formulations, which include additional antigens for diseases like hepatitis B and Hib. These innovations reduce the number of injections required for comprehensive immunization programs. Johnson & Johnson, GSK, Serum Institute, Bionet-Asia, and Meiji Holdings are some of the prominent players in the DPT vaccine space.
In 2023, Sanofi Pasteur launched Hexacima a six in a one immunization Vaccine in the U.S. market.
In 2022, Merck & Co. collaborated with Thermos to enhance vaccine storage and distribution technologies.